NL-OMON45993撤回不适用
Optimal blood pressure control through improved adherence to antihypertensive medication after shared decision making in people with type 2 diabetes (T2DM) - INTENSE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Adults (>18 years) with T2DM AND
- •2. BP >140/90 mm Hg ( people * 80 years) or
- •> 160/90 mmHg (people > 80 years, based on Dutch guidelines), measured during the last-check up at the general practice/ endocrinologist using a 30-minute bloodpressure monitor. AND
- •3. use of three adequately dosed antihypertensive medications, including a diuretic during at least the past 3 months
排除标准
- •1. type 1 diabetes;
- •2. eGFR < 30 ml/min;
- •3. a history of alcoholism or drug abuse;
- •4. dementia or major psychiatric disorder that is likely to invalidate informed consent (IC), or limit the ability of the individual to comply with the protocol requirements.
- •5. Unwillingness to provide a written informed consent.
- •6. Pregnancy
研究者
相似试验
进行中（未招募）
不适用
Study of the efficacy of two blood pressure lowering drugs, ramipril and nifedipine GITS, in reducing the variability of blood pressure in patients with high blood pressure.EUCTR2014-003459-76-GRIstituto Auxologico Italiano, IRCCS168
进行中（未招募）
1 期
Study of the efficacy of two blood pressure lowering drugs, ramipril and nifedipine GITS, in reducing the variability of blood pressure in patients with high blood pressure.essential hypertensionMedDRA version: 17.1Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2014-003459-76-ITIstituto Auxologico Italiano, IRCCS168
已完成
4 期
Treatment Optimisation for Blood Pressure with Single-Pill combinations in IndiaCTRI/2022/04/042106Imperial College1,981
已完成
不适用
Effectiveness of community intervention programHypertensionISRCTN88146057Griffith University (Australia)1,600
已完成
3 期
BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstemHypertensionNCT01482364Hemo Sapiens, Inc.183